Want to see KR:017180 full AI Analyst Report?
Top Page
MYUNGMOON Pharm Co., Ltd.
(017180)
Select Model
Select Model
Rating:45Neutral
Price Target:
₩1,159.00
Action:N/A
Date:10/28/26
The score is primarily constrained by weak financial quality—ongoing losses in TTM and negative operating/free cash flow—despite strong revenue growth. Technicals add pressure as the stock trades below key moving averages with negative MACD and muted RSI. Valuation also screens poorly due to a negative P/E and no provided dividend yield.
Positive Factors
Strong Revenue Expansion
Strong revenue expansion indicates growing demand for the company’s pharmaceutical products and broader market reach. If sustained, this top-line momentum can improve operating leverage, support investment in the portfolio, and strengthen the company’s position with medical institutions and distribution channels.
Negative Factors
Volatile Profitability
Repeated swings between profit and loss show that revenue growth has not yet translated into dependable earnings. A renewed TTM loss weakens internal funding capacity and makes results more sensitive to cost control, product mix, and execution over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Expansion
Strong revenue expansion indicates growing demand for the company’s pharmaceutical products and broader market reach. If sustained, this top-line momentum can improve operating leverage, support investment in the portfolio, and strengthen the company’s position with medical institutions and distribution channels.
Read all positive factors
MYUNGMOON Pharm Co., Ltd. (017180) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩38.88B
Dividend Yield1.67%
Average Volume (3M)167.03K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue Growth4.75%
EPS Growth-237.25%
CountryKR
Employees309
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-60.35
Shares Outstanding33,953,453
10 Day Avg. Volume87,304
30 Day Avg. Volume167,025
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)0.64
Price to Sales (P/S)0.32
P/FCF Ratio-7.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MYUNGMOON Pharm Co., Ltd. Business Overview & Revenue Model
Company Description
MYUNGMOON Pharm Co., Ltd. operates as a pharmaceutical enterprise, comprehensively handling the research, development, production, distribution, and commercialization of medicinal products. Its business activities extend across South Korea and int...
MYUNGMOON Pharm Co., Ltd. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 199.82B | 195.25B | 186.44B | 169.57B | 152.13B | 137.76B |
| Gross Profit | 114.43B | 107.19B | 104.97B | 95.35B | 78.10B | 62.34B |
| EBITDA | 5.26B | 10.13B | 5.67B | 4.52B | 10.63B | 790.68M |
| Net Income | -1.67B | 1.90B | -3.03B | -4.52B | 7.87B | -6.80B |
Balance Sheet | ||||||
| Total Assets | 300.16B | 272.46B | 257.99B | 236.55B | 230.45B | 223.26B |
| Cash, Cash Equivalents and Short-Term Investments | 24.31B | 6.15B | 4.76B | 11.66B | 9.98B | 10.52B |
| Total Debt | 87.15B | 98.63B | 87.51B | 90.48B | 83.16B | 84.13B |
| Total Liabilities | 197.52B | 168.00B | 154.87B | 147.79B | 135.18B | 137.39B |
| Stockholders Equity | 97.59B | 98.74B | 96.85B | 83.45B | 89.52B | 80.26B |
Cash Flow | ||||||
| Free Cash Flow | -9.91B | -8.46B | -2.74B | -8.17B | 3.53B | 480.28M |
| Operating Cash Flow | -3.55B | -1.70B | -1.34B | -5.18B | 5.47B | 855.00M |
| Investing Cash Flow | -6.55B | -7.20B | 967.90M | 1.82B | -4.93B | 9.08B |
| Financing Cash Flow | 25.70B | 10.32B | -3.22B | 6.45B | -2.50B | -7.68B |
MYUNGMOON Pharm Co., Ltd. Technical Analysis
Negative
―
Price Trends
1248.44
Negative
1243.16
Negative
1508.64
Negative
Market Momentum
-15.40
Positive
37.68
Neutral
29.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:017180, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 1256.00, equal to the 50-day MA of 1248.44, and equal to the 200-day MA of 1508.64, indicating a bearish trend. The MACD of -15.40 indicates Positive momentum. The RSI at 37.68 is Neutral, neither overbought nor oversold. The STOCH value of 29.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:017180.
MYUNGMOON Pharm Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₩53.37B | 4.90 | ― | 3.12% | 6.69% | 220.70% | |
58 Neutral | ₩144.41B | 7.86 | ― | 4.70% | 6.59% | 185.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₩435.39B | -884.82 | ― | 0.08% | 6.21% | 95.65% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
50 Neutral | ₩169.19B | 63.80 | ― | 3.22% | 1.83% | -67.89% | |
45 Neutral | ₩38.88B | -19.14 | ― | 1.67% | 4.75% | -237.25% |
* General Sector Average
KR:017180
MYUNGMOON Pharm Co., Ltd.
1,163.00
-439.00
-27.40%
KR:000020
Dong Wha Pharm Co., Ltd.
5,210.00
-990.45
-15.97%
KR:000220
Yuyu Pharma, Inc.
3,690.00
-398.53
-9.75%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
95.20
2.60%
KR:003220
Daewon Pharmaceutical Co., Ltd
7,760.00
-5,120.31
-39.75%
KR:019170
Shinpoong Pharmaceutical Co., Ltd.
8,460.00
-5,550.00
-39.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.